HMGA2 and acute myeloid leukemia: Importantly, an extensive recent clinical study that included samples from more than 350 human de novo AML patients treated with TOP2 poisons alone or in combination with DNA synthesis inhibitors implicated HMGA2 expression in leukemic cells to poor clinical outcomes (Marquis et al., 2018).